For years, the global defence industry existed in a sort of polite exile.  In the era of ESG mandates and the "peace dividend ...

Somnigroup International (NYSE:SGI) reached an agreement to acquire Leggett & Platt (NYSE:LEG) in an all-stock transaction valued at approximately $2.5 billion, a move that unites the world's largest ...

The a2 Milk Company (ASX:A2M) has reported a mismatch between surging consumer demand and supply chain capacity for its infant milk formula business in China. According to a trading update released ...

Talius Group (ASX:TAL) has secured a master services agreement with Seventh-Day Adventist Aged Care (South Queensland), operating as Adventist Retirement Plus. The partnership marks an expansion for ...

Great Northern Minerals (ASX:GNM) announced a landmark expansion into the world-class Battle Mountain-Cortez Trend with the strategic acquisition of the Iron Butte Gold-Silver Project. Situated in ...

Tivan (ASX:TVN) announced the appointment of Robert Gerrard as COO, effective April 20. Gerrard brings over 18 years of executive experience in the Australian resources and energy sectors, having ...

Prime Minister Anthony Albanese has ruled out means-testing the National Disability Insurance Scheme, reaffirming the programme's commitment to universality despite its ballooning $55.1 billion price ...

Genmab (NASDAQ:GMAB) presented new data at the 2026 Society of Gynecologic Oncology (SGO) Annual Meeting on Monday, demonstrating that its investigational antibody-drug conjugate (ADC), rinatabart ...

Logistics giant Brambles (ASX:BXB) is bracing for a potential compensation bill exceeding $100 million following a landmark Federal Court ruling that found the company misled investors over its ...

Amgen (NASDAQ:AMGN) has announced positive topline results from its Phase 3 clinical trial evaluating a subcutaneous formulation of TEPEZZA (teprotumumab-trbw) for adults with moderate-to-severe ...

Medicus Pharma (NASDAQ:MDCX) has reached a critical regulatory milestone, submitting an optimized Phase 2 clinical trial protocol to the U.S. Food and Drug Administration (FDA) for its lead candidate, ...

Outlook Therapeutics (NASDAQ:OTLK), a biopharmaceutical company working to develop the first FDA-approved ophthalmic formulation of bevacizumab, announced on April 7, 2026, that the U.S. Food and Drug ...